Immunosuppressive acidic protein (IAP) serum levels in breast cancer

M. Quaranta, M. Coviello, V. Lorusso, C. Rella, G. Micelli, G. C. Torre

Research output: Contribution to journalArticlepeer-review


Immunosuppressive acidic protein (IAP) serum levels were determined by single radial immunodiffusion in 180 women with breast cancer, in 33 with benign breast disease and in 66 healthy controls. IAP cut-off value was set at 550 μg/ml (mean for the control group plus 2SD). Higher values were found in 4/48 (8%) women with benign breast disease and in 80/180 (44%) patients (pts) with breast carcinoma considering all stages. In particular, with regard to the stage of disease, elevated IAP levels were observed in 6/50 (12%) pts with negative axillary limphnodes (N-), in 45/95 (47%) pts with positive limphnodes (N+) and in 29/35 (83%) pts with metastatic disease. Among healthy subjects only 2/66 (3%) women showed elevated serum IAP levels. Our preliminary data show that IAP is a reliable tumor marker in advanced breast cancer, therefore it can be useful in monitoring the clinical course of the disease. Moreover it may aid in postoperative follow-up, detecting relapse or metastasis and may be recommended as an addition to diagnostic procedures.

Original languageEnglish
Pages (from-to)191-194
Number of pages4
JournalJournal of Tumor Marker Oncology
Issue number2
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Immunosuppressive acidic protein (IAP) serum levels in breast cancer'. Together they form a unique fingerprint.

Cite this